Orforglipron for PCOS and weight loss: sorting hype from trial data

What did @bossfidence actually say?

The creator reported that Eli Lilly shares jumped 13% after orforglipron, a daily oral GLP-1 drug, completed a Phase 3 trial with results appearing comparable to injectable GLP-1 medications. They also flagged a quirk in the Forbes headline, noting that Ozempic and Mounjaro are the diabetes brand names, and that Wegovy and Zepbound would have been more accurate comparisons for weight loss. They then speculated that this pill could be a game-changer for women with PCOS who already take metformin, and suggested it might shift outcomes in women's health and fertility.

That is a fairly packed set of claims for a 60-second TikTok, and not all of them hold up equally well under scrutiny. Let's work through them.

Does the science back this up?

The Phase 3 data on orforglipron is real and it is genuinely notable. The trial showed meaningful weight loss results, but calling it "as effective as Ozempic" flattens important differences in the numbers.

The ATTAIN Phase 3 trial (Eli Lilly, 2025, presented at ADA and published in The New England Journal of Medicine) reported that orforglipron produced approximately 7.9% to 8.7% mean body weight reduction over 36 weeks depending on the dose arm. For comparison, semaglutide 2.4mg (Wegovy) in the STEP 1 trial (Wilding et al., 2021, NEJM) produced around 14.9% mean weight reduction over 68 weeks, and tirzepatide (Zepbound) in SURMOUNT-1 (Jastreboff et al., 2022, NEJM) hit up to 20.9% over 72 weeks. The trials used different durations and populations, so you cannot do a clean apples-to-apples comparison. But the gap is not trivial, and the Forbes framing of "as effective" was doing a lot of work.

On the PCOS and metformin angle, there is currently no published Phase 3 data specifically in PCOS populations for orforglipron. Extrapolating from general weight loss trials to a specific endocrine condition and then connecting that to fertility outcomes is a significant leap.

What did they get wrong (or right)?

Credit where it is due: the creator's correction about brand names was accurate. Ozempic is semaglutide indicated for type 2 diabetes, Wegovy is semaglutide indicated for weight management. Mounjaro is tirzepatide for type 2 diabetes, Zepbound is tirzepatide for weight management. Mixing these up in a weight loss context, as the Forbes headline did, is a real error, and the creator caught it.

Where they went wrong is in treating Phase 3 trial results as a near-certain preview of clinical equivalence to existing injectables. Phase 3 completion means the drug showed safety and efficacy sufficient to support an FDA submission. It does not mean it performs identically to drugs with longer trial durations and higher absolute weight loss numbers. The claim that women with PCOS can now "have very similar results to if they were doing an injection" is not supported by current published evidence. GLP-1 receptor agonists have shown promise in PCOS research, for example Jensterle et al. (2022, Frontiers in Endocrinology) on liraglutide, but orforglipron has not been studied specifically in that population in Phase 3 yet.

What should you actually know?

Orforglipron is a small-molecule oral GLP-1 receptor agonist, which means it does not have the same protein structure limitations as oral semaglutide (Rybelsus), which requires strict fasting and water protocols to absorb properly. That is a legitimate practical advantage and worth paying attention to as more data emerges.

However, an FDA approval has not yet been granted. Eli Lilly has filed for approval, but regulatory review takes time and can include requests for additional data. The drug is not available yet, and no one should be making treatment decisions based on Phase 3 press releases and stock movement headlines.

For people with PCOS who are on metformin and curious about GLP-1 options, there are already approved injectable options with actual PCOS-adjacent evidence. A conversation with an endocrinologist or reproductive endocrinologist using existing approved medications is the appropriate path, not waiting on a drug that has not cleared FDA review and has zero published data in that specific population.

The fertility angle is particularly speculative. Weight loss can improve ovulatory function in people with PCOS, but connecting a pill that has not been approved, studied in PCOS patients, or compared head-to-head with metformin to fertility outcomes is a stretch. That is not a health claim that should be floated without serious qualification.